Sensei Biotherapeutics, Inc., a biotechnology company focused on cancer treatment, reported its financial results for the first quarter of 2026, highlighting a net loss of $170.2 million, compared to a loss of $6.9 million in the same quarter of the previous year. The company noted a substantial increase in research and development expenses, which rose to $18.0 million, largely due to the integration of Faeth Therapeutics' operations following its acquisition and related one-time costs. As of March 31, 2026, Sensei's cash and marketable securities stood at $202.8 million, a significant increase from $21.2 million at the end of 2025. The company’s lead program, PIKTOR, is currently undergoing a Phase 1b/2 trial for HR+/HER2- advanced breast cancer, with interim results expected in 2027. Additionally, topline data from a Phase 2 trial in advanced endometrial cancer is anticipated in the latter half of 2026. Sensei's strategic moves, including the acquisition and new capital infusion, are aimed at advancing its innovative cancer therapies.